Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3717 Comments
1726 Likes
1
Safoora
Loyal User
2 hours ago
{协议答案}
👍 129
Reply
2
Kimura
New Visitor
5 hours ago
{协议答案}
👍 150
Reply
3
Gerry
Consistent User
1 day ago
{协议答案}
👍 54
Reply
4
Kalex
New Visitor
1 day ago
{协议答案}
👍 243
Reply
5
Autunm
Trusted Reader
2 days ago
{协议答案}
👍 272
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.